Side effects of anti-TNF α therapy in juvenile idiopathic arthritis;Effetti collaterali del trattamento con inibitori del TNFα nell'artrite idiopatica giovanile

Reumatismo

Volumn 58, Issue 1, 2006, Pages 31-38

  Pontikaki, Irene ^a,b   Gerloni, Valeria ^a   Gattinara, Maurizio ^a   Lurati, Alfredomaria ^a   Salmaso, Alessandra ^a   De Marco, Gabriele ^a   Teruzzi, Barbara ^a   Valcamonica, Elisabetta ^a   Fantini, Flavio ^a  

^a ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Adverse events; Anti TNF therapy; JIA

Indexed keywords

ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADOLESCENT; ARTICLE; BEHAVIOR DISORDER; BEHAVIOR MODIFICATION; CHILD; CONTROLLED STUDY; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DRUG INDUCED DISEASE; FEMALE; HEADACHE; HUMAN; HYPOGLOSSAL NERVE DISEASE; IRIDOCYCLITIS; JUVENILE RHEUMATOID ARTHRITIS; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; NERVE PARALYSIS; PAIN; SIDE EFFECT; THROMBOCYTOPENIA; THYROID CANCER; TREATMENT DURATION; TUBERCULOSIS; ADULT; CARCINOMA; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CYTOMEGALIC INCLUSION BODY DISEASE; DISEASE PREDISPOSITION; DRUG ANTAGONISM; HEMATURIA; IMMUNE DEFICIENCY; INFECTION; PRESCHOOL CHILD; PSORIATIC ARTHRITIS; THYROID TUMOR; VIRUS PNEUMONIA;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ARTHRITIS, JUVENILE RHEUMATOID; ARTHRITIS, PSORIATIC; CARCINOMA; CHILD; CHILD BEHAVIOR DISORDERS; CHILD, PRESCHOOL; CROHN DISEASE; CYTOMEGALOVIRUS INFECTIONS; DISEASE SUSCEPTIBILITY; FEMALE; HEADACHE; HEMATURIA; HUMANS; HYPOGLOSSAL NERVE DISEASES; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULIN G; INFECTION; IRIDOCYCLITIS; MALE; METHOTREXATE; PNEUMONIA, VIRAL; RECEPTORS, TUMOR NECROSIS FACTOR; THROMBOCYTOPENIA; THYROID NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33746521117     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141-7.
2. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000; 342: 763-9.
3. Lipsky PE. Infliximab and MTX in the treatment of Rheumatoid Arthritis. N Engl J Med 2000; 343: 1594-601.
4. Johnson CJ, Reilly KM, Murray KM. Etanercept in Juvenile Rheumatoid Arthritis. Ann Pharmacother 2001; 35: 464-71.
5. Haapasaari J, Kautiainen H, Hannula S, Pohjankoski H, Hakala M. Good results from combining etanercept to prevailing DMARD therapy in refractory juvenile idiopathic arthritis. Clin Exp Rheumatol 2002; 20: 867-70.
6. Takei S, Groh D, Bernstein B, Shaham B, Gallagher K, Reiff A. Safety and efficacy of high dose etanercept in treatment of juvenile rheumatoid arthritis. J Rheumatol. 2001; 28: 1677-80.
7. Kietz DA, Pepmueller PH, Moore TL. Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period. Ann Rheum Dis 2002; 61: 171-3.
8. Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003; 48: 1093-101
9. Ramanan AV, Schneider R. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol 2003; 30: 401-3.
10. Lovell DJ, Giannini EH, Reiff A, Jones OY, Schneider R, Olson JC, et al. Pediatric Rheumatology Collaborative Study Group. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 2003; 48: 218-26.
11. Reiff A, Takei S, Sadeghi S, Stout A, Shaham B, Bernstein B, et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001; 44: 1411-5.
12. Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban 1997. J Rheumatol 1998; 25: 1991-4
13. Bloom BJ. Development of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 2000; 43: 2606-8.
14. Lepore L, Marchetti F, Facchini S. Drug-induced systemic lupus erythematosus associated with etanercept therapy in a child with juvenile idiopathic arthritis. Clin Exp Rheumatol 2003; 21: 276-7.
15. Skytta E, Pohjankoski H, Savolainen A. Etanercept and urticaria in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol 2000; 18: 533-4.
16. Elwood RL, Pelszynski MM, Corman LI. Multifocal septic arthritis and osteomyelitis caused by group A Streptococcus in a patient receiving immunomodulating therapy with etanercept. Pediatr Infect Dis J 2003; 22: 286-8.
17. Havell EA. Evidence that tumour necrosis factor has an important role in a antibacterial resistance. J Immunol 1989; 143: 2894-9.
18. Pfeffer K, Matsuyama T, Kündig TM, Wakeham A, Kishihara K, Shahinian A, et al. Mice deficient for the 55kd tumour necrosis factor receptor are resistant to endotoxic shock, yet succumb to L monocytogenes infection. Cell 1993; 73: 457-67.
19. Cope AP, Londei M, Chu NR, Cohen SB, Elliott MJ, Brennan FM, et al. Chronic exposure to TNFα in vitro impairs the activation of T cells through the T cell receptor/CD3 complex: reversal in vivo by anti-TNFα antibody in patients with rheumatoid arthritis. J Clin Invest 1994; 94: 749-60.
20. Lahdenne P, Vahasalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 2003;62: 245-7.
21. Gerloni V, Pontikaki I, Gattinara M, Desiati F, Lupi E, Lurati A, et al. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, Infliximab, in persistently active, refractory juvenile idiopathic arthritis: Results of an open label prospective study Arthritis Rheum 2005; 52: 548-53.
22. Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 2000; 59: 1341-59.